Company Overview

Better Therapeutics, Inc. (NASDAQ: BTTX) was a digital therapeutics company focused on developing prescription software-based treatments for cardiometabolic diseases. The company operated within the digital health, healthcare technology, and therapeutic software industries, with a primary emphasis on behavioral medicine delivered through mobile applications. Its core strategy centered on using cognitive behavioral therapy and other behavioral interventions to address underlying lifestyle factors associated with chronic diseases such as type 2 diabetes, hypertension, and related metabolic conditions.

The company’s principal product candidate and commercial asset was BT-001, a prescription digital therapeutic designed for adults with type 2 diabetes. Better Therapeutics positioned itself as an evidence-based healthcare technology company seeking regulatory validation through clinical trials and U.S. Food and Drug Administration authorization pathways. The company evolved from a broader wellness and behavioral health focus into a regulated prescription digital therapeutics model after its founding in 2015. Better Therapeutics became publicly traded through a merger with a special purpose acquisition company in 2021. Public disclosures and market filings later indicated significant financial distress, and available public records show the company substantially reduced operations and pursued strategic alternatives. Data regarding ongoing commercial activity is inconclusive based on available public sources.

Business Operations

Better Therapeutics primarily operated through a single integrated digital therapeutics business focused on software-enabled disease management. Revenue generation efforts were tied to commercialization and reimbursement initiatives for prescription digital therapeutics, particularly BT-001. The company’s platform incorporated behavioral science methodologies, including nutritional counseling frameworks and cognitive behavioral therapy techniques, delivered through mobile software applications intended to modify patient behaviors associated with chronic disease progression.

Operations were concentrated primarily in the United States, where the company conducted clinical trials, regulatory engagement, and commercialization planning. Better Therapeutics controlled proprietary digital therapeutic software assets and clinical data generated through studies intended to support FDA authorization and payer adoption. The company collaborated with healthcare providers, payers, and research organizations to evaluate adoption pathways for prescription digital therapeutics. Public filings identified limited international operational exposure, and there were no major long-term international joint ventures or global operating subsidiaries disclosed in available SEC documentation.

Strategic Position & Investments

Better Therapeutics pursued a strategy centered on expanding the clinical legitimacy of digital therapeutics through randomized clinical trials, FDA regulatory submissions, and payer engagement. Its growth initiatives focused on developing additional software-based therapeutic candidates targeting hypertension, hyperlipidemia, and broader cardiometabolic disease categories. The company sought to differentiate itself from general wellness applications by emphasizing prescription-only deployment, physician oversight, and clinical evidence generation.

The company invested substantially in software development, clinical validation, and regulatory infrastructure rather than physical healthcare assets. BT-001 received FDA authorization in 2023 as a prescription digital therapeutic for type 2 diabetes, representing a significant milestone for the company and the broader digital therapeutics sector. However, SEC filings and public disclosures later reflected liquidity constraints, workforce reductions, and strategic reviews intended to preserve capital. Data regarding active investment activity, acquisitions, or continuing product expansion following these restructuring efforts is inconclusive based on available public sources.

Geographic Footprint

Better Therapeutics maintained its headquarters in California, United States, and its operational footprint was concentrated primarily within the U.S. healthcare market. Clinical development, regulatory activities, and commercialization initiatives were directed toward U.S. physicians, patients, and healthcare payers due to the company’s emphasis on FDA-regulated prescription digital therapeutics.

The company did not disclose a broad multinational operating infrastructure comparable to larger pharmaceutical or healthcare technology firms. While its software-based delivery model theoretically supported scalability across international markets, public filings and corporate disclosures primarily referenced domestic commercialization efforts. Available public information does not indicate substantial operational influence across Europe, Asia-Pacific, or other major international healthcare regions.

Leadership & Governance

Better Therapeutics was founded by entrepreneurs and healthcare technology executives seeking to apply behavioral medicine principles to chronic disease management through software-based interventions. The company’s leadership emphasized clinical validation, regulatory engagement, and integration with traditional healthcare systems as central components of its strategic vision.

Key executives and leadership figures publicly associated with the company included:

• Frank Karbe – Chief Executive Officer
• Kevin Appelbaum – Chief Financial Officer
• Mark Berman, M.D. – Chief Medical Officer
• Parth Shah – Co-Founder and former Chief Executive Officer
• Janice MacAvoy – Board Chair and Director

Leadership communications in public filings and investor materials consistently emphasized evidence-based treatment development, payer adoption strategies, and the long-term role of prescription digital therapeutics in chronic disease care. Governance oversight was conducted through the company’s board of directors in accordance with public company reporting standards outlined in SEC filings and related corporate governance disclosures.